Skip to main content
Chison Medical Technologies Co.,Ltd. logo

Chison Medical Technologies Co.,Ltd. — Investor Relations & Filings

Ticker · 688358 ISIN · CNE1000076R4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2021-12-29 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688358

About Chison Medical Technologies Co.,Ltd.

https://www.chison.com/

Chison Medical Technologies Co.,Ltd. specializes in the research, development, and manufacturing of diagnostic ultrasound systems. The company offers a comprehensive portfolio of medical imaging solutions, including trolley-based color Doppler systems, portable ultrasound units, and specialized handheld devices. Its products integrate advanced imaging technologies such as 4D imaging, artificial intelligence-assisted diagnostics, and high-resolution transducers to support clinical applications in cardiology, obstetrics, gynecology, and point-of-care settings. Chison focuses on delivering high-performance diagnostic tools to healthcare providers, supported by a global network of research centers and distribution channels. The company emphasizes continuous innovation in digital signal processing and transducer technology to enhance diagnostic accuracy and clinical workflow efficiency.

Recent filings

Filing Released Lang Actions
国金证券股份有限公司关于无锡祥生医疗科技股份有限公司2021年度持续督导现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2021年度持续督导现场检查报告" (2021 Annual Continuous Supervision On-site Inspection Report) by the sponsor institution Guojin Securities for Wuxi Xiangsheng Medical Technology Co., Ltd. It details the sponsor's on-site inspection covering governance, internal controls, information disclosure, independence, use of raised funds, related party transactions, guarantees, major investments, and operational status during the continuous supervision period in 2021. The document references regulatory requirements from the China Securities Regulatory Commission and Shanghai Stock Exchange rules. It is a detailed report of the sponsor's inspection findings rather than a general annual report or earnings release. It is not a brief announcement or a certification letter but a substantive report on the continuous supervision inspection. This type of document aligns with an Audit Report / Information (AR) category, as it is a standalone inspection report related to regulatory compliance and internal controls, not a full annual report or earnings release. FY 2021
2021-12-29 Chinese
国金证券股份有限公司关于无锡祥生医疗科技股份有限公司核心技术人员离职的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution regarding the departure of a core technical staff member at a company preparing for an initial public offering. It discusses personnel changes, confidentiality agreements, impact on R&D projects, and the company's ongoing technical capabilities. There is no financial data, no earnings or annual report content, no voting results, no capital changes, and no regulatory certifications. The document is a regulatory disclosure related to personnel changes and their impact on the company, typical of a regulatory filing or announcement. Given the nature and length (3146 characters) and the content, it fits best under Regulatory Filings (RNS) as it does not match any other specific category such as management changes (MANG) which usually focus on board or senior management changes, not core technical staff, nor is it a report or announcement of a report publication. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2021-12-29 Chinese
祥生医疗关于公司核心技术人员离职的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the resignation of a core technical staff member at Wuxi Xiangsheng Medical Technology Co., Ltd. It details the departure of Mr. Wang Yong, his confidentiality and non-compete obligations, the impact on the company, and the company's measures to maintain R&D capabilities. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no indication of a report being attached or published. The content is about management personnel changes specifically related to a key technical employee, which fits the category of Board/Management Information (MANG). The document length is short (2965 characters), and it is a standalone announcement about personnel change, not a report or presentation.
2021-12-29 Chinese
祥生医疗关于全资子公司开立募集资金专项账户并签订募集资金专户存储三方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Wuxi Xiangsheng Medical Technology Co., Ltd. regarding the opening of special accounts for raised funds by its wholly-owned subsidiary and the signing of a tripartite supervision agreement for the storage of raised funds. It details the background of the fundraising, the establishment of special accounts, the signing of agreements with the bank and the sponsor institution, and the terms of these agreements. The document does not contain financial statements or detailed financial performance data. It is primarily an update on capital management and regulatory compliance related to fundraising activities. The document length is 3661 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best under the category of Capital/Financing Update (CAP).
2021-12-07 Chinese
国金证券关于祥生医疗首次公开发行战略配售限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a formal opinion from a sponsoring securities company regarding the listing and circulation of restricted shares related to a company's initial public offering (IPO) on the Shanghai Stock Exchange's STAR Market. It details the type of restricted shares, the number of shares becoming tradable, compliance with relevant laws and regulations, and confirms that the shareholder has fulfilled their commitments. The document is not a financial report, earnings release, or management discussion, but rather a regulatory compliance and verification statement related to share listing and circulation. It does not announce voting results, changes in management, or capital changes, but is a regulatory filing related to share circulation compliance. The document length is short (1968 characters) and it is a formal verification opinion, fitting best under Regulatory Filings (RNS).
2021-11-25 Chinese
祥生医疗首次公开发行战略配售限售股上市流通公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the listing and circulation of restricted shares from the company's initial public offering (IPO) strategic placement shares. It details the number of shares becoming freely tradable after the expiration of the lock-up period, the relevant dates, shareholder commitments, and verification by the sponsoring institution. There are no financial statements or detailed financial data presented, and the document is relatively short (1864 characters). It is not a full financial report but an official announcement about share circulation related to capital changes. This fits the category of Share Issue/Capital Change (SHA) rather than a full report or regulatory filing.
2021-11-25 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.